Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Xynomic Pharmaceuticals Holdings, Inc. (XYNO) had Normalized Income after Taxes of $-25.10M for the most recently reported fiscal year, ending 2019-12-31.
| Income Statement Financials | |
-- |
|
$-26.80M |
|
-- |
|
-- |
|
$25.04M |
|
$-25.04M |
|
$-0.07M |
|
$-25.10M |
|
$-25.10M |
|
$-25.10M |
|
$-25.10M |
|
$-25.10M |
|
|
Normalized Income after Taxes |
$-25.10M |
$-25.04M |
|
$-24.97M |
|
32.28M |
|
32.28M |
|
$-0.83 |
|
$-0.83 |
|
| Balance Sheet Financials | |
$0.42M |
|
$0.29M |
|
$0.51M |
|
$0.94M |
|
$23.50M |
|
-- |
|
-- |
|
$23.50M |
|
$-22.56M |
|
$-22.56M |
|
$-22.56M |
|
46.27M |
|
| Cash Flow Statement Financials | |
$-10.67M |
|
$63.26M |
|
$-57.22M |
|
$4.75M |
|
$0.09M |
|
$-4.65M |
|
$8.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.02 |
|
-- |
|
-- |
|
-- |
|
-0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.72M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
111.26% |
|
111.25% |
|
-2677.69% |
|
111.26% |
|
$-0.49 |
|
$-0.33 |
|
$-0.33 |
|